AstraZeneca: Fasenra Trial In EoE Did Not Meet One Of Two Du

LONDON (dpa-AFX) - British drug major AstraZeneca PLC (AZN.L) Tuesday announced that MESSINA Phase III trial for Fasenra (benralizumab) failed to meet one of the two dual-primary endpoints in eosinophilic

Related Keywords

Japan , United Kingdom , London , City Of , British , , Astrazeneca , Biowa Inc , Kyowa Kirin Co Ltd , More Such Health News , Executive Vice President , Fasenra , Trial , Feet , Ual , Primary , Endpoints ,